Braskem 2Q26: EBITDA Soars to $1B, But Default and D-Rating Loom
BAK sits 16% above its 52-week low of $2.03.
Summary
Braskem reported 2Q26 Recurring EBITDA of US$1.0 billion, a massive improvement from 1Q26, but disclosed it is in default on certain debt and its credit rating was cut to D by S&P.
Key Events · Earnings and Guidance · BAK
-
EBITDA Surges to $1B
2Q26 Recurring EBITDA reached US$1.0 billion, up from US$192 million in 1Q26, driven by higher international spreads for resins and chemicals due to the Middle East conflict.
-
Net Income Turns Positive
Net income attributable to shareholders was US$664 million in 2Q26, compared to a loss in 1Q26, reflecting the EBITDA improvement.
-
Default and Downgrade
The company is in default under certain financial instruments as of July 2026, and S&P downgraded its global credit rating to D on June 26, 2026.
-
Debt Restructuring Continues
Braskem remains in mediation with creditors, with no agreement reached. Its Mexican subsidiary Braskem Idesa is considering Chapter 11 under U.S. law.
Analysis · BAK · Industrial Applications And Services
Braskem's 2Q26 results show a dramatic EBITDA surge to US$1.0 billion from US$192 million in 1Q26, driven by Middle East conflict-driven spreads. However, the company is now in default on certain financial obligations, has been downgraded to D by S&P, and its Mexican subsidiary is considering Chapter 11. The earnings beat is overshadowed by the deepening restructuring crisis.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BAK was trading at $2.35 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $726M. The 52-week trading range was $2.03 to $5.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.